A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Part of paid clinical trials in Brooklyn, Maryland.

Sponsor
AstraZeneca
Study ID
NCT07216131
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • AZD0780 — DRUG
    AZD0780 will be administered orally.
  • Metformin — DRUG
    Metformin will be administered orally.

Study Details

The purpose of this study is to determine how the experimental medication AZD0780 impacts the pharmacokinetics (PK) of metformin, a common medication used to treat type 2 diabetes mellitus, when given together in healthy participants.

Key Dates

Start date
Nov 10, 2025
Status verified
Jan 2026
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
14 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Metformin/Metformin + AZD0780
    Participants will receive a single dose of metformin on Day 1 in Treatment Period 1 followed by a washout period of 7 days. In Treatment Period 2, participants will receive a single dose of AZD0780 followed by a single dose of metformin on Day 8.

Primary Outcome Measure

Area under concentration time curve from time 0 to infinity (AUCinf) [ Time Frame: Days 1 to 3 and Days 8 to 10 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteBrooklynMaryland21225-

Find similar trials in Brooklyn, MD

By research site
Research Site· Brooklyn, MD

Related Studies